Droxidopa / Pyridostigmine in Orthostatic Hypotension
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/12/2018 |
| Start Date: | November 2011 |
| End Date: | June 2019 |
| Contact: | Tonette Gehrking |
| Email: | adc.research@mayo.edu |
| Phone: | 507-284-0336 |
Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension
The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural
transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE).
This combination should result in enhanced orthostatic release of NE. The investigators have
already demonstrated that pyridostigmine does not raise supine blood pressure.
transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE).
This combination should result in enhanced orthostatic release of NE. The investigators have
already demonstrated that pyridostigmine does not raise supine blood pressure.
1. The presence of orthostatic hypotension (fall in systolic BP greater than or equal to
30 mm Hg) is required for this study;
2. Autonomic testing and clinical evaluation demonstrates OH to be of neurogenic
etiology.
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Phillip A. Low, MD
Phone: 507-284-0336
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
